Azacitidine Combined With Chidamide in the Treatment of Newly Diagnosed PTCL Unfit for Conventional Chemotherapy

Inclusion Criteria: * Pathologically confirmed peripheral T-cell lymphoma based on 2016 WHO classification * Treatment naive * Age ≥ 18 years * Unfit for converntional chemotherapy meeting criteria as following but not limited to: age ≥75, ECOG \>2，ADL\<100 or CCI\>1. * Must has measurable lesion in CT or PET-CT prior to treatment * Expected lifetime ≥ 3 months * Informed consented Exclusion Criteria: * Has accepted localized or systemic anti-lymphoma treatment * Has accepted autologous Stem cell transplantation before * History of malignancy except for basal cell or squamous cell carcinoma of the skin or carcinoma in situ of the cervix prior to study treatment * Uncontrollable cardio-cerebral vascular, coagulative, autoimmune, serious infectious disease * Primary CNS lymphoma * Left EF≤ 50% * Lab at enrollment (Unless caused by lymphoma): Neutrophile\<1.5\*10\^9/ L ;Platelet\<75\*10\^9/L; ALT or AST \>2\*ULN; Creatinine\>1.5\*ULN * Other uncontrollable medical condition that may that may interfere the participation of the study * Not able to comply to the protocol for mental or other unknown reasons * Patients with mentally disorders or other reasons unable to fully comply with the study protocol * Pregnant or lactation * HIV infection * HBV-DNA and HCV-RNA undectable.